CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the clinical or regulatory front. These relatively small drugmakers look highly promising thanks to their incredible, innovative potential.

That's why investors keep bidding up their shares -- although Viking has been the better performer of the two, by a mile, over the past year. So which one of these two stocks will outperform the other over the long run? Let's find out.

Continue reading

Source Fool.com